Wells Fargo & Company Point Biopharma Global Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$6.67 - $9.71 $29,508 - $42,957	-4,424 Reduced 5.95%	69,934 $466,000
Q2 2023 Aug 15, 2023	BUY	$6.86 - $10.86 $153,170 - $242,482	22,328 Added 42.91%	74,358 $673,000
Q1 2023 May 12, 2023	BUY	$6.78 - $8.1 $305,303 - $364,743	45,030 Added 643.29%	52,030 $378,000
Q4 2022 Feb 13, 2023	SELL	$5.72 - $9.78 $12,378 - $21,163	-2,164 Reduced 23.61%	7,000 $51,000
Q3 2022 Nov 14, 2022	SELL	$7.24 - $10.31 $3,142 - $4,474	-434 Reduced 4.52%	9,164 $70,000
Q2 2022 Aug 12, 2022	BUY	$5.6 - $9.5 $12,034 - $20,415	2,149 Added 28.85%	9,598 $66,000
Q1 2022 May 16, 2022	BUY	$5.46 - $8.13 $5 - $8	1 Added 0.01%	7,449 $60,000
Q4 2021 Feb 14, 2022	BUY	$4.83 - $9.75 $4 - $9	1 Added 0.01%	7,448 $42,000
Q3 2021 Nov 15, 2021	BUY	$7.42 - $11.26 $55,256 - $83,853	7,447 New	7,447 $57,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.